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OBJECTIVE: Lichen planus is a chronic inflammatory autoimmune mucocutaneous disease. Recent research has
emphasized the strong association between inflammation and both P-wave dispersion and dyslipidemia. The
difference between the maximum and minimum P-wave durations on an electrocardiogram is defined as P-
wave dispersion. The prolongation of P-wave dispersion has been demonstrated to be an independent risk
factor for developing atrial fibrillation. The aim of this study was to investigate P-wave dispersion in patients
with lichen planus.
METHODS: Fifty-eight patients with lichen planus and 37 age- and gender-matched healthy controls were
included in this study. We obtained electrocardiographic recordings from all participants and used them to
calculate the P-wave variables. We also assessed the levels of highly sensitive C-reactive protein, which is an
inflammatory marker, and the lipid levels for each group. The results were reported as the means ¡ standard
deviations and percentages.
RESULTS: The P-wave dispersion was significantly higher in lichen planus patients than in the control group.
Additionally, highly sensitive C-reactive protein, LDL cholesterol, and triglyceride levels were significantly
higher in lichen planus patients compared to the controls. There was a significant positive correlation between
highly sensitive C-reactive protein and P-wave dispersion (r = 0.549, p,0.001) in lichen planus patients.
CONCLUSIONS: P-wave dispersion increased on the surface electrocardiographic measurements of lichen planus
patients. This result may be important in the early detection of subclinical cardiac involvement. Increased P-
wave dispersion, in terms of the tendency for atrial fibrillation, should be considered in these patients.
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& INTRODUCTION
Lichen planus (LP) is a chronic inflammatory disease that
affects the skin, genitalia, mucous membranes, and appen-
dages (1). Although its etiology and pathogenesis are not
fully understood, it is believed that LP represents a T-cell-
mediated inflammatory disorder. Inflammation produces
lipid metabolism disturbances, such as serum increases in
triglycerides and low-density lipoprotein cholesterol (LDL-
C) and decreases in high-density lipoprotein cholesterol
(HDL-C) (2).
Chronic inflammation, lipid disturbances, and oxidative
stress are also thought to be responsible for the increased
prevalence of cardiovascular diseases (2,3). Psoriasis, which
is a chronic inflammatory skin disease similar to LP, is
associated with a high frequency of cardiovascular events
(4). An increased risk for cardiovascular risk factors, such as
hypertension, obesity, diabetes mellitus, dyslipidemia, and
metabolic syndrome, has been reported in patients with
psoriasis (4,5). LP has also been associated with dyslipide-
mia(2,6), diabetes mellitus(7), and increased oxidative stress
(8).
P-wave dispersion (PWD) can be measured on an
electrocardiogram (ECG), and it is regarded as an electro-
cardiographic marker of prolonged intra-atrial and inter-
atrial conduction time in addition to the heterogeneous and
discontinuous propagation of sinus impulses (9). The
propagation of electrical activity in the atrial myocardium
causes a different conduction rate and atrial re-entry
because of the shortening of the refractory period. Atrial
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re-entry is an electrophysiological mechanism that plays an
important role in atrial fibrillation development.
Prolongation in PWD is related to an increased risk of
atrial fibrillation development in patients with various heart
diseases (10,11) and sleeping disorders, such as obstructive
sleep apnea (12). PWD has been reported to be influenced
by autonomic tone, which induces changes in atrial size and
the velocity of impulse propagation (13). Increased PWD
has been demonstrated to be an independent risk factor for
developing atrial fibrillation (AF, the most common
sustained arrhythmia in the general population); it also
increases cardiovascular morbidity and mortality and
decreases quality of life (14). A PWD value of 40 ms has
been used in previous research to separate patients with
paroxysmal AF from control subjects; studies using this
method have reported that this PWD value has a sensitivity
of 83% and a specificity of 85% (15).
In 2012, Ahlehoff et al. (16) investigated the relationship
between psoriasis and atrial fibrillation; they reported that
atrial fibrillation was increased in psoriasis patients.
Bacaksiz et al. (3) found that P-wave dispersion was
increased in psoriasis patients. Both studies demonstrated
that a chronic inflammatory disorder, such as psoriasis,
might increase the risk of developing atrial fibrillation. In
the present study, we aimed to investigate the risk of
developing atrial arrhythmia in LP, which is recognized as a
chronic disease that displays a similar physiopathology as
psoriasis. However, we have not found any studies in the
literature that indicated a relationship between LP and atrial
fibrillation. A large number of serial studies must be
performed to determine the incidence of atrial fibrillation
in LP. The aim of the current study was to evaluate P-wave
dispersion in LP patients.
& MATERIALS AND METHODS
Patients
Fifty-eight LP patients and 37 age-, body mass index
(BMI)-, and gender-matched healthy controls were included
in this clinical study. All subjects underwent clinical
examinations and provided detailed medical histories,
including the presenting complaints, illness history, pre-
vious drug usage (including gold salts, beta blockers,
thiazide diuretics, furosemide, spironolactone, antimalar-
ials, penicillamine, antihypertension, nonsteroidal anti-
inflammatory drugs, and tetracycline), dentistry treatment,
smoking, alcohol intake, and other lifestyle habits and
concomitant diseases. None of the patients were on systemic
treatments at the time of investigation. LP was diagnosed
according to clinical assessment, histological study, and
immunofluorescence examination. All subjects provided
informed consent, and the study was approved by the local
ethics committee.
Clinical and Biochemical Parameters
The participants’ weights and heights were measured,
and their BMIs (kg/m2) were calculated. Systolic and
diastolic blood pressures were measured after a 5-minute
rest and again 10 minutes later; the mean value of both
measurements was used. Serum triglycerides, LDL-C,
glucose levels, and highly sensitive C-reactive protein (hs-
CRP) levels were determined in samples collected between
8 and 9 AM after a 12-hour fasting period.
Echocardiographic examination
The echocardiographic examination was performed at
rest, with the patient in a left, lateral, decubitus position,
using a commercially available echocardiographic device
(Vivid 3, General Electric) with a 3 MHz transducer; this test
was performed by 2 experienced echocardiographers who
were blinded to the clinical data. Long-axis measurements
were obtained at the level distal to the mitral valve leaflets
using M-mode echocardiography according to current
recommendations (17). The left ventricular ejection fraction
was calculated via a modified biplane Simpson’s method
from apical four- and two-chamber views. The pulsed
Doppler sampling volume was placed between the tips of
the mitral valve leaflets to obtain maximum filling velo-
cities. The early diastolic flow (E), atrial contraction signal
(A), and E deceleration time (DT) were measured. The
isovolumetric relaxation time (IVRT) was defined as the
interval between the end of the aortic outflow and the
beginning of the mitral inflow signal.
Twelve-lead electrocardiogram and P-wave
duration analysis
Twelve-lead ECGs were obtained after a 10-minute rest
with 20-mm/mV amplitude and 50-mm/sec rates with
standard lead positions in a supine position using commer-
cially available machinery (Marquette Case, Hellige Medical
System, Cardiosmart Hellige Instrument Company,
Freiburg, Germany). The beginning of the P-wave was
defined as the point at which the first atrial deflection
crossed the isoelectric line; the end of the P-wave was
defined as the point at which the atrial deflection returned
to the isoelectric line. The P-wave durations (Pmax and
Pmin) were calculated in all 12 ECG leads (Figure 1). The
difference between Pmax and Pmin was defined as PWD
(18).
All measurements were performed by 2 experienced
cardiologists who were blinded to the patient’s clinical
status. The measurements were obtained manually with the
help of calipers and a magnifying glass to define the
electrocardiographic deflection. After completing the man-
ual measurements, PWD was tested to identify the intra-
observer and inter-observer variability in 30 randomly-
selected patients using the Bland-Altman method (19). The
95% limits of agreement for PWD were acceptable (26.4 to
6.7 ms and 29.8 to 9.9 ms; respectively) (Figures 2A and
2B).
Figure 1 - The P-wave durations (Pmax and Pmin) were calculated
in all 12 ECG leads.
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Statistical analysis
The results were expressed as the mean ¡ SD. The data
between the groups were compared using SPSS (ver. 13).
Student’s t-test was used for continuous variables, the chi-
squared test was used for categorical variables, and the
Mann-Whitney U-test was used for variables without
normal distributions. Pearson’s correlation analysis was
performed to assess the correlation between variables. In
addition, a multivariate analysis of variance (MANOVA)
was performed to compare groups of whole continuous
variables in the tables. A two-tailed p-value of, 0.05 was
considered significant.
& RESULTS
Fifty-eight LP patients (30 females [51.7%] and 28 males
[48.3%]) were included in the study. The patient ages
ranged from 17 to 70 years (mean age, 43.42¡14.58 years).
They were age and gender matched with 37 healthy controls
(mean age, 39.32¡11.67 years). The disease duration ranged
from 4 months to 6 years (mean, 29.62¡17.39 months).
Cutaneous lesions were present in all 58 cases. Mucosal
lesions were present in 31 patients (53.4%) in the form of
white, reticular streaks on the buccal mucosa. None of the
patients had erosive oral LP. Nail involvement was also
present in 38 patients (65.5%) in the form of ridging,
grooving, and longitudinal striations. Thirty-one patients
(53.4%) presented with classic LP, 17 patients (29.3%) had
the actinic type, and 10 patients (17.2%) had the hyper-
trophic type. The descriptive, demographical characteristics
of the groups are shown in Table 1.
According to the MANOVA results, there was a statisti-
cally significant difference between the continuous variables
in the two groups (Wilks’ lambda distribution = 0.007,
p= 0.001). However, when the univariate analysis results
were considered, there were no statistically significant
differences between the groups in terms of age, gender,
cigarette smoking, height, weight, or BMI. The mean systolic
and diastolic blood pressures and heart rates were also
similar between the groups. Echocardiographic variables,
including the LV ejection fraction, LA dimension, and
diastolic Doppler indices, were not significantly different
between the groups (Table 2). The biochemical data,
including serum glucose levels, were not significantly
different between the groups, but the hs-CRP (3.5¡2.6
versus 1.7¡1.1, respectively, p,0.001), LDL cholesterol
Figure 2 - Bland-Altman plots demonstrating the 95% limits of agreement between (A) the repeated measurements of PWD by the
same observer and (B) between the manual measurement of PWD by two different observers in 30 randomly selected patients.






Age (years) 43.4¡14.5 39.3¡11.6 NS
Male (n, %) 28 (48.3%) 19 (51%) NS
Smoking (n, %) 22 (37.9%) 10 (27%) NS
BMI (kg/m2) 26.7¡3.7 25.2¡2.8 NS
Fasting glucose (mg/dL) 85.9¡7.74 86.3¡8.8 NS
LDL cholesterol (mg/dL) 129.6¡31.7 96.8¡33.6 ,0.001
Triglycerides (mg/dL) 169.2¡93.6 110.5¡52.7 0.001
hs-CRP (mg/L) 3.5¡2.6 1.7¡1.1 ,0.001
Systolic BP (mmHg) 128¡8.5 123¡12.9 NS
Diastolic BP (mmHg) 76.5¡11.5 78¡7.8 NS
BMI: body mass index, BP: blood pressure, HR: heart rate, hs-CRP: highly
sensitivity C-reactive protein, LDL: low-density lipoprotein, HDL: high-
density lipoprotein, NS: statistically non-significant.







LVEDD (mm) 45.9¡4.3 47.0¡3.6 NS
LVESD (mm) 26.3¡4.9 28.3¡4.1 NS
LV ejection fraction (%) 67¡5.1 68¡3.0 NS
LA diameter (mm) 33.8¡4.4 33.9¡3.8 NS
Doppler echocardiography
E (cm/sn) 79.0¡17.5 86.0¡9.1 NS
A (cm/sn) 65.1¡10.0 67.5¡9.5 NS
EDT (ms) 218.1¡46.1 208.2¡34.9 NS
IVRT (ms) 88.6¡22.6 79.7¡13.9 NS
LVESD: Left ventricle end-systolic diameter, LVEDD: left ventricle end-
diastolic diameter, LV: left ventricle, LA: left atrium, E: peak mitral valve
flow velocity during the early rapid filling phase, A: peak mitral valve flow
velocity during atrial contraction, EDT: deceleration time of early phase of
mitral valve flow; IVRT = isovolumetric relaxation time.
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(129.6¡31.7 versus 96.8¡33.6, respectively, p,0.001), and
triglyceride (169.2¡93.6 versus 110.5¡52.7, respectively,
p=0.001) levels were significantly higher in the LP patients
compared to the controls (Table 1).
Pmax and PWD were significantly higher in LP patients
than in the control groups (78.44¡14.14 versus 68.64¡11.88,
respectively, p= 0.001; 39.9¡12.9 versus 32.4¡11.8, respec-
tively, p= 0.005). Pmin was not significantly different
between the groups (Table 3). In addition, there was a
significant, positive correlation between hs-CRP and PWD
(r = 0.549, p,0.001) in the LP patients.
& DISCUSSION
The major findings of this study are as follows: (i) LP
patients had a significantly higher PWD compared to
healthy subjects; (ii) the lipid and hs-CRP levels were
higher in LP patients than in healthy subjects; and (iii) PWD
was significantly correlated with hs-CRP.
Lichen planus is a chronic autoimmune mucocutaneous
disease that affects the oral mucosa, skin, genital mucosa,
scalp, and nails (20). The disease occurs in 0.4-1.9 percent of
the population, mostly middle-aged patients and particu-
larly women (7,21). The exact pathogenesis of the disease
remains unclear, but both antibodies and T-cell mediation
have been implicated. Activated T-cells release cytokines,
leading to the attraction of inflammatory cells and the
destruction of keratinocytes through cell-mediated cytotoxi-
city (22). It has also been suggested that increased reactive
oxygen species and lipid peroxides may affect the patho-
genesis of LP (23). Studies have shown that LP is associated
with extreme cardiovascular risks, including dyslipidemia
(2,6), diabetes mellitus (7), and increased oxidative stress (8).
Most cardiovascular disorders (including atherosclerosis,
hypertension, insulin-resistance, dyslipidemia, and arrhyth-
mias) share similar pathogenetic mechanisms, such as
chronic inflammation, endothelial dysfunction, and
increased oxidative stress (24).
LP has been reported to be associated with dyslipidemia
in some studies (2,6,25). Some drugs used for dyslipidemia
have been associated with lichen planus-like eruption, and
many drugs used to treat lichen planus (e.g., systemic
corticosteroids, retinoic acid, and methotrexate) have also
been associated with dyslipidemia. Psoriasis, which is
another chronic inflammatory skin disease, has been
recently related to dyslipidemia (26). The frequent presence
of chronic inflammation parameters in patients with
psoriasis has been used to suggest a relationship with
cardiovascular disease. Several cytokines, such as TNF-a,
IL-2, and IL-6, have been implicated in the increased lipid
levels in these patients (2). Otherwise, LP is an immune-
mediated disease; antigens are processed by Langerhans
cells and then presented to T-lymphocytes. This stimulated
lymphocytic infiltrate is epidermotropic and attacks kerati-
nocytes, resulting in the generation of reactive oxygen
species. During this lymphocytotoxic process, keratinocytes
release more cytokines that, in turn, attract more lympho-
cytes. The cytokines involved in LP pathogenesis (such as
TNF-a, IL-6, IL-10, and IL-4) could explain the association
with dyslipidemia (2).
Some studies have hypothesized that inflammatory
markers, such as hs-CRP, may provide an adjunctive
method to globally assess cardiovascular risk (27,28). The
ongoing inflammation might affect the myocardium, and
increased inflammatory activity is almost always associated
with poor cardiac prognosis. Increased hs-CRP levels
demonstrate the activity of this chronic disease and are an
independent risk factor for arrhythmias (29). Recent studies
have found a close association between atrial fibrillation and
inflammation; atrial fibrillation was found to be more
common in cases with high hs-CRP levels following
coronary bypass (30) and acute pericarditis (31).The
estimation of PWD, which is a reliable, non-invasive, and
feasible variable with good reproducibility of intra- and
inter-atrial heterogeneity, could be a useful method of
identifying patients who are prone to suffer from AF.
Several studies have shown that PWD has a predictive value
for atrial fibrillation in patients with various conditions
(18,32). Increased hs-CRP levels and the correlation between
PWD and hs-CRP in our study indicated that inflammation
might be a possible mechanism for increased PWD in LP.
Many inflammatory diseases, such as rheumatoid arthritis
(33), psoriasis (3), and systematic lupus erythematosus, have
increased PWD, which may indicate that prolonged PWD
depends on these diseases rather than itself to promote
inflammation.
We demonstrated prolonged PWD using surface ECG in
LP patients without other conditions that could increase
PWD, such as coronary artery disease, systolic heart failure
(ejection fraction ,45%), hypertension, arrhythmia, anti-
arrhythmic treatment, obesity (BMI.35 kg/m2), valve dis-
ease, pulmonary hypertension, sleep apnea syndrome,
chronic obstructive lung disease, and neurological disease.
To the best of our knowledge, this study is the first to
demonstrate prolonged PWD and atrial conduction delay in
LP patients without additional systemic disease. Although
LP is a disease characterized by increased inflammatory
activity, no clinical data exist regarding whether atrial
inflammation and the risk of AF are increased in these
patients. Furthermore, we do not have any knowledge
regarding the relationship between the incidence of AF and
inflammation in this special patient group. In future studies,
it will be important to investigate the prevalence of AF and
the relationship between atrial fibrillation and the degree of
inflammation in LP patients.
Limitations
The small number of LP patients and lack of long-term
clinical follow-up are major limitations to our study.
Automated ECG measurements were not available, and
manual calculations of P-wave measurements may be
subject to error. Whether increased PWD in patients with
LP predicts poorer clinical outcomes or mandates any
special treatment warrants further study.
In conclusion, the present study showed that PWD
increased on surface ECG measurements in LP patients.
This result may be an early detection of subclinical cardiac





Pmax 78.44¡14.14 68.64¡11.88 0.001
Pmin 38.62¡5.44 36.48¡6.95 0.098
PWD 39.9¡12.9 32.4¡11.8 0.005
Pmax: Maximum P-wave duration, Pmin: minimum P-wave duration,
PWD: P-wave dispersion.
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involvement. Increased PWD should be considered, in
terms of tendency to AF, in these patients. We suggest that
long-term LP patients be considered for referral for
cardiovascular evaluation. Larger studies with longer
follow-up are necessary to evaluate any clinical implications
of our findings.
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